GI Pathology Hires VP of Marketing
GI Pathology PLLC has tapped Raymond L. Compagna as the company’s vice president of marketing and business development. He will lead GI Pathology’s marketing function and new business development efforts.

“Ray brings significant experience to GI Pathology in positioning health care products and companies,” says William E. McDowell, senior vice president and general manager of GI Pathology. “Having someone of Ray’s caliber to help shape the GI Pathology message will give our company an enhanced marketing program and help us expand our business.”

Compagna has more than 13 years of sales and marketing experience in the medical device and diagnostic industries. Before joining GI Pathology, he was the director of marketing for Meridian Bioscience.

King Succeeds MacMahon at LabCorp
David P. King has been selected to succeed Thomas P. MacMahon as CEO of LabCorp® on January 1, 2007. To help ensure a smooth transition, following his retirement as CEO on December 31, MacMahon will continue to serve as chairman of the board of directors for a period expected to last until the annual shareholders’ meeting in 2008. The board has also approved the appointment of Bradford T. Smith to the board of directors as vice chairman, effective January 1, 2007.

King joined LabCorp in 2001 after working for many years with the company as an outside counsel. Since 2005, he has served as executive vice president and COO. Prior to that, he served as head of the company’s Esoterix and US LABS businesses, and as executive vice president of strategic planning and development.

Low Becomes Chairman of Tm Bioscience Advisory Board
Tm Bioscience Corp has appointed Donald Low, PhD, chairman of its scientific advisory board. With more than 30 years of experience, Low is recognized worldwide as an authority in the area of emerging infectious diseases.

“Developing products for infectious-disease testing, one of the largest market opportunities for DNA-based diagnostics, is a key focus of our company,” says Greg Hines, president and CEO of Tm Bioscience. “We welcome Dr Low and anticipate that his expertise and guidance will prove invaluable as we advance our flagship infectious-disease test, the ID-Tag™ respiratory viral panel (RVP), through the regulatory-clearance and commercialization processes.”

“Tm’s core Universal Array technology enables products that could more rapidly and cost-effectively identify and discriminate between multiple infectious-disease organisms in a clinical setting, leading to improved treatment responses. In particular, Tm’s ID-Tag RVP represents a significant new tool that could significantly improve how respiratory viral infections are identified and managed,” Low says. “I look forward to my involvement in advancing this truly innovative technology.”

Low is a professor of medicine and microbiology at the University of Toronto; head of the Division of Microbiology in the Department of Laboratory Medicine and Pathobiology at the University of Toronto; medical director of Public Health Laboratories; and chief of the Toronto Medical Laboratories and Mount Sinai Hospital Department of Microbiology.

The Tm scientific advisory board meets regularly to advise management on the selection and development of new DNA-based diagnostic products, and to provide recommendations on regulatory and commercialization strategies for the company’s growing menu of genetic tests.